# Abdominal Obesity, Hepatic Steatosis, Oxidative Stress and Diastolic Dysfunction in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

**Authors:** Luca Colangeli, Ilaria Milani, Maria Eugenia Parrotta, Susanna Longo, Alessandro Nucera, Massimo Federici, Simonetta Palleschi, Barbara Rossi, Alessandro Mantovani, Saverio Muscoli, Frida Leonetti, Danila Capoccia, Paolo Sbraccia, Valeria Guglielmi

PMC · DOI: 10.3390/ijms27041968 · International Journal of Molecular Sciences · 2026-02-18

## TL;DR

This study finds that abdominal obesity and liver disease are closely linked to heart issues in older patients with obesity.

## Contribution

The study identifies abdominal obesity as a mediator between liver disease and heart dysfunction in older patients with MASLD.

## Key findings

- Diastolic dysfunction was common in patients with MASLD and obesity.
- Abdominal obesity mediates the association between liver steatosis and heart dysfunction.
- Oxidative stress markers were not directly linked to heart dysfunction or liver disease severity.

## Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a key contributor to the development of heart failure with preserved ejection fraction in individuals with obesity. This study aimed to investigate whether MASLD and diastolic dysfunction are independently associated with abdominal obesity through shared metabolic and oxidative mechanisms. We conducted a cross-sectional study in a tertiary university hospital including patients aged ≥ 50 years with obesity and MASLD. Clinical, anthropometric, biochemical, and oxidative stress parameters were collected, and hepatic steatosis and fibrosis were assessed using vibration-controlled transient elastography (FibroScan®). Patients were stratified according to the presence or absence of echocardiographic diastolic dysfunction. A total of 73 patients was included in the analysis and 27.4% had diastolic dysfunction. Patients with diastolic dysfunction were older and had higher body weight, body mass index (BMI) and waist circumference. Markers of hepatic steatosis, including fatty liver index (FLI) and controlled attenuation parameter (CAP), were higher in patients with diastolic dysfunction, whereas fibrosis measures were not. CAP was independently associated with diastolic dysfunction after adjustment for age and sex, but this association was lost after further adjustment for waist circumference, suggesting a mediating role of central adiposity. Plasma glutathione was inversely associated with FLI, but oxidative stress markers were not associated with diastolic dysfunction or steatosis severity. In conclusion, in patients ≥ 50 years with MASLD and obesity, diastolic dysfunction was common and closely related to abdominal obesity, highlighting MASLD as a multisystem condition with early cardiac involvement.

## Linked entities

- **Diseases:** Metabolic dysfunction-associated steatotic liver disease (MONDO:0013209)

## Full-text entities

- **Genes:** GGT1 (gamma-glutamyltransferase 1) [NCBI Gene 2678] {aka CD224, D22S672, D22S732, GGT, GGT 1, GGTD}, GGTLC4P (gamma-glutamyltransferase light chain 4 pseudogene) [NCBI Gene 729838] {aka GGT}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, NR0B2 (nuclear receptor subfamily 0 group B member 2) [NCBI Gene 8431] {aka SHP, SHP1}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, FLII (FLII actin remodeling protein) [NCBI Gene 2314] {aka CMD2J, FLI, FLIL, Fli1}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, SLC5A2 (solute carrier family 5 member 2) [NCBI Gene 6524] {aka SGLT2}
- **Diseases:** Abdominal Obesity (MESH:D056128), primary biliary cholangitis (MESH:D008105), cardiac abnormalities (MESH:D018376), hepatocellular carcinoma (MESH:D006528), Metabolic Dysfunction (MESH:D008659), Lipid overload (MESH:D011017), necrosis (MESH:D009336), hemochromatosis (MESH:D006432), autoimmune hepatitis (MESH:D019693), hypertriglyceridemia (MESH:D015228), primary sclerosing cholangitis (MESH:D015209), HFpEF (MESH:D054144), visceral adiposity (MESH:D007418), CAP (MESH:C538265), OSAS (MESH:D020181), T2D (MESH:D003924), Hepatic steatosis (MESH:D005234), Diastolic Dysfunction (MESH:D018487), hypercholesterolemia (MESH:D006937), arrhythmias (MESH:D001145), structural or functional (MESH:D020914), HF (MESH:D006333), abdominal adiposity (MESH:D000007), hypo-HDL (MESH:D052456), Tricuspid regurgitation (MESH:D014262), adipose tissue dysfunction (MESH:D018205), Obesity (MESH:D009765), Cardiac hypertrophy (MESH:D006332), drug-induced liver injury (MESH:D056486), cardiac remodeling (MESH:D020257), cardiac dysfunction (MESH:D006331), LSM (MESH:D017093), cardiovascular disease (MESH:D002318), ischemic heart disease (MESH:D017202), atrial fibrillation (MESH:D001281), diabetes (MESH:D003920), malignancies (MESH:D009369), hyper-LDL (MESH:D006938), hepatic and myocardial fibrosis (MESH:D008103), diastolic impairment (MESH:D006337), insulin resistance (MESH:D007333), injury to (MESH:D014947), adipose tissue inflammation (MESH:D007249), Metabolic Dysfunction-Associated Steatotic Liver Disease (MESH:D008107), Fibrosis (MESH:D005355), metabolic disturbances (MESH:D024821), myocardial remodeling (MESH:D064752), myocardial alterations (MESH:D004408), LVH (MESH:D017379), Hypertension (MESH:D006973), hyperinsulinemia (MESH:D006946), hypothyroidism (MESH:D007037), Dyslipidemia (MESH:D050171), Alcohol Use Disorders (MESH:D000437), mitochondrial dysfunction (MESH:D028361)
- **Chemicals:** Alcohol (MESH:D000438), creatinine (MESH:D003404), glucose (MESH:D005947), cholesterol (MESH:D002784), ROS (MESH:D017382), cysteinylglycine (MESH:C028505), calcium (MESH:D002118), glutathione (MESH:D005978), FFA (MESH:D005230), lipid (MESH:D008055), cysteine (MESH:D003545), thiol (MESH:D013438), Cr (MESH:D002857), homocysteine (MESH:D006710), triglycerides (MESH:D014280), fatty acid (MESH:D005227), AOPP (-), S (MESH:D013455), TG (MESH:D013866), TC (MESH:D013667), sodium (MESH:D012964), oxygen (MESH:D010100), disulfide (MESH:D004220)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940709/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12940709/full.md

## References

73 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940709/full.md

---
Source: https://tomesphere.com/paper/PMC12940709